Teva Pharmaceutical Industries マネジメント

マネジメント基準チェック /24

Teva Pharmaceutical Industriesの CEO はRichard Francisで、 Jan2023年に任命され、の在任期間は 1.83年です。の年間総報酬は$ 25.71Mで、 6.2%給与と93.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.011%を直接所有しており、その価値は€ 1.92M 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と7.3年です。

主要情報

Richard Francis

最高経営責任者

US$25.7m

報酬総額

CEO給与比率	6.2%
CEO在任期間	1.8yrs
CEOの所有権	0.01%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	7.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Teva Pharmaceutical Industries の収益と比較して、Richard Francis の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$959m
Jun 30 2024	n/a	n/a	-US$453m
Mar 31 2024	n/a	n/a	-US$478m
Dec 31 2023	US$26m	US$2m	-US$559m

報酬と市場: Richardの総報酬 ($USD 25.71M ) は、 Austrian市場 ($USD 4.29M ) の同規模の企業の平均を上回っています。

報酬と収益: Richardの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Richard Francis (56 yo)

1.8yrs

在職期間

US$25,706,880

報酬

Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard Francis	President	1.8yrs	US$25.71m	0.011% € 1.9m
Eliyahu Kalif	Executive VP & CFO	4.9yrs	US$4.94m	0.064% € 11.3m
Mark Sabag	Executive Vice President of International Markets Commercial	3.3yrs	US$3.73m	0.028% € 4.9m
Richard Daniell	Executive Vice President of European Commercial	7yrs	US$5.16m	0% € 0
Matthew Shields	Executive Vice President of Global Operations	less than a year	データなし	データなし
Amir Weiss	Senior VP & Chief Accounting Officer	3yrs	データなし	0.00046% € 81.3k
Ran Meir	Head of Investor Relations	no data	データなし	データなし
Kathleen Veit	Senior Vice President	2.3yrs	データなし	データなし
David Mcavoy	Executive VP & Chief Legal Officer	less than a year	データなし	データなし
Placid Jover	Executive VP & CHRO	less than a year	データなし	データなし
Kevin Mannix	Senior Vice President of Investor Relations	no data	データなし	データなし
Nir Baron	Senior VP & Chief Internal Auditor	10.5yrs	データなし	データなし

2.7yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: TEVAの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Richard Francis	President	no data	US$25.71m	0.011% € 1.9m
Sol Barer	Independent Chairman of the Board	9.8yrs	US$539.99k	0.036% € 6.4m
Amir Elstein	Independent Director	15.8yrs	US$340.00k	0.18% € 32.7m
Gerald Lieberman	Independent Director	9.2yrs	US$355.00k	0.0094% € 1.7m
Roberto Mignone	Independent Director	7.3yrs	US$340.00k	0.0084% € 1.5m
Rosemary Crane	Independent Director	9.2yrs	US$330.00k	0.0091% € 1.6m
Janet Vergis	Independent Director	4.4yrs	US$325.46k	0.0056% € 999.1k
Tal Zaks	Independent Director	3.1yrs	US$330.00k	0.0043% € 767.5k
Perry Nisen	Independent Director	7.3yrs	US$327.87k	0.0084% € 1.5m
Ronit Satchi-Fainaro	Independent Director	6.4yrs	US$315.25k	0.0078% € 1.4m
Varda Shalev	Independent Director	1.2yrs	US$176.66k	0.0011% € 201.6k

7.3yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: TEVAの取締役会は経験豊富であると考えられます ( 7.3年の平均在任期間)。

Teva Pharmaceutical Industries マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Recent updates

Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023)

Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.77 loss in 2Q 2023)

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine

Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024

Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States

Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2023)

Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024

Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China

Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2022)

Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024

New major risk - Share price stability

Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents

Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity

Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.05 in 3Q 2022)

Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business

Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Share price stability

Teva Announces Changes to Executive Management Team

Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023

Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings released: US$0.77 loss per share (vs US$0.21 loss in 2Q 2022)

Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023

Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023

Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study

Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY

Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States

Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.86 loss in 1Q 2022)

Full year 2022 earnings released: US$2.12 loss per share (vs US$0.38 profit in FY 2021)

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023

Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023

Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million.

Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.27 in 3Q 2021)

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims

Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022

Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression

Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc

Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021)

Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer

Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022

Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia

Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.07 profit in 1Q 2021)

Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022

Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S

Chief Accounting Officer Andrew Weil has left the company

Third quarter 2021 earnings released: EPS US$0.27 (vs US$3.97 loss in 3Q 2020)

Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims

Forecast to breakeven in 2021

マネジメント基準チェック /24